Eclipsys sees Q3 income slide

Health IT company Eclipsys has released its 2009 third quarter results, which ended Sept. 30, posting a 95.6 percent loss in net income compared with the 2008 third quarter.

The Atlanta-based company reported that its net income during the 2009 third quarter was $3.9 million, compared with the 2008 third quarter figure of $87.4 million. This year's third quarter results were partially attributable to a repaid debt of $45 million on its credit facility. Also, the net income in the third quarter of 2008 included a one-time income tax benefit of $80 million associated with the reversal of the company’s deferred tax valuation allowance.

According to Eclipsys, revenues for the third quarter saw a $6.9 million downturn from last year's quarterly figure--the 2009 third quarter revenues ended with $125.5 million, compared with revenues of $132.4 million for same year-ago quarter.

Eclipsys did see a reduction of 3.7 percent in overall total costs and expenses, with its 2009 third quarter costs and expenses totaling $120.9 million, compared with $125.6 million in the 2008 third quarter.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.